Xeris Biopharma Holdings
XERS
103 hedge funds and large institutions have $91.3M invested in Xeris Biopharma Holdings in 2022 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 24 closing their positions.
1,243% more call options, than puts
Call options by funds: $2.79M | Put options by funds: $208K
12% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 25
6.5% more ownership
Funds ownership: 37.25% → 43.75% (+6.5%)
8% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 24
0% more funds holding
Funds holding: 103 → 103 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
29% less capital invested
Capital invested by funds: $129M → $91.3M (-$37.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$12.7M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$7.86M |
| 3 |
State Street
Boston,
Massachusetts
|
+$3.66M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.29M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lazard Asset Management
New York
|
-$3.86M |
| 2 |
AC
Armistice Capital
New York
|
-$3.46M |
| 3 |
Millennium Management
New York
|
-$1.86M |
| 4 |
Goldman Sachs
New York
|
-$1.29M |
| 5 |
Man Group
London,
United Kingdom
|
-$1.13M |
XERS Hedge Fund Activity: Q2 2022 in Review
103 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q2 2022, worth a combined $91.3M — down 29% from $129M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new XERS positions and 24 closed out — a net gain of 2 holders — while 28 added to existing stakes and 25 trimmed.
The largest buyer was BlackRock, adding an estimated $12.7M. The largest seller was Lazard Asset Management, cutting an estimated $3.86M.
- 103 institutional investors held Xeris Biopharma Holdings (XERS) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $91.3M of Xeris Biopharma Holdings stock for Q2 2022, down 29% quarter-over-quarter.
- 26 funds opened new Xeris Biopharma Holdings positions in Q2 2022 and 24 closed out, a net change of +2 holders.
- The largest Xeris Biopharma Holdings buyer in Q2 2022 was BlackRock, an estimated $12.7M added.
- The largest Xeris Biopharma Holdings seller in Q2 2022 was Lazard Asset Management, an estimated $3.86M sold.
Based on aggregated 13F filings for Q2 2022.